The Marburg virus belongs to the family Filoviridae and is closely related to the Ebola virus. It causes severe and often fatal hemorrhagic fever in humans and non-human primates, with sporadic outbreaks reported in Africa. Named after the German city where the first known outbreak occurred in 1967, the Marburg virus is transmitted to humans through direct contact with infected animals or their bodily fluids. Human-to-human transmission can occur through close contact with the blood, organs, or other bodily fluids of infected individuals. The virus's incubation period ranges from 2 to 21 days, with symptoms including fever, severe headache, malaise, and, in later stages, hemorrhagic manifestations. There is no specific antiviral treatment for Marburg virus disease, and supportive care is the mainstay of management. Efforts to control Marburg virus outbreaks involve isolation of infected individuals, contact tracing, and strict infection prevention measures. Research continues to enhance our understanding of the virus, develop potential vaccines and antiviral therapies, and improve public health responses to minimize the impact of Marburg virus disease.
Title : Personalized and Precision Medicine (PPM) via biodesign-driven translational applications and upgraded business modeling to secure the human biosafety: The next-step vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : The promise of nanotechnology in Personalized & Precision Medicine: Nano-driven precision vaccinomics of the future
Sergey V Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Recombinant BCG vaccine as a potent anti tuberculosis vaccine candidate
Sajal Dey, BRIC-Centre for DNA Fingerprinting and Diagnostics, India
Title : Emerging nanovaccine strategies for enhanced immune targeting and vaccine performance
Aysel Sadayli, V.Y. Axundov Scientific-Research Institute of Medical Prophylaxis, Azerbaijan
Title : Advancing vaccine availability and equity in low-resource settings: Evidence from Awendo Sub-County, Kenya
Millicent Ochieng, Clinton Health Access Initiative, Kenya
Title : Reaching zero-dose children through adaptive immunization strategies in security-compromised areas of Zamfara State, Nigeria
Attahir Abubakar, Ahmadu Bello University, Nigeria
Title : From local pilots to national policy: Key issues and challenges in implementing nationwide HPV vaccination in China
Shenglan Tang, Duke Global Health Institute, United States